

## Supplementary materials

### Materials and methods

#### Plasmid constructs

The cDNA encoding CKIP-1 was generated by PCR from the human 22-week fetal liver cDNA library. All deletion and point mutants of CKIP-1, c-Jun and others were generated by PCR or recombinant PCR, followed by subcloning into: (i) yeast two-hybrid plasmids pGBKT7 and pGADT7 (Clontech); (ii) pGEX-4T-2 (Pharmacia) for expression in bacteria; (iii) pCMV-Myc (Clontech), or pFlag-CMV-2 (Sigma) to express N-terminal Myc or Flag-tagged protein, and pcDNA3.1-Myc (version C) (Invitrogen) to express C-terminal Myc-tagged protein (and for stable transfection); (iv) pSP72 (Promega) for *in vitro* translation; (v) pEGFP-C1, pDsRed1-N1 (Clontech) to express GFP or RFP-fused protein.

The restriction endonuclease enzymes used in the subcloning were listed below.

- (i) pGADT7-CKIP-1/C-term1/ $\Delta$ C-term1, *NdeI/EcoRI*
- (ii) pGBKT7-c-Jun/bzJun/lzJun/ $\Delta$ bzJun/ $\Delta$ lzJun/bzJunD/bzJunB/bzFos/bzATF2, *NdeI/EcoRI*
- (iii) pcDNA3.1-myc-CKIP-1/CKIP-D310+345A, *HindIII/KpnI*;  
pCMV-Myc-CKIP-1/C-term1/C-term2/ $\Delta$ C-term1/ $\Delta$ C-term2/c-Jun, *EcoRI/KpnI*; pFlag-CMV-2-CKIP-1/c-Jun, *EcoRI/KpnI*; pCMV-Myc-Bax, *EcoRI/XhoI*
- (iv) pSP72-CKIP-1 wild-type and all mutants, *EcoRI/KpnI*
- (v) pGEX-4T-2-CKIP-1, *EcoRI/NotI*; pGEX-4T-2-PH, *EcoRI/XhoI*;

pGEX-4T-2-c-Jun, *BamHI/XhoI*

- (vi) pDsRed1-N1-CKIP-1/C-term1/ $\Delta$ C-term1/ $\Delta$ PH, *EcoRI/KpnI*,  
pEGFP-C1-c-Jun, *EcoRI/KpnI*


### **Transfections, cell culture**

Monkey kidney COS7 cells, human embryonic kidney HEK293 cells, and mouse fibroblast NIH3T3 cells were cultured in DMEM containing 10% fetal bovine serum (FBS). SK-BR-3 and MCF7 breast cancer cells, human cervix carcinoma HeLa cells, MOLT4 leukemia cells were maintained in RPMI 1640 containing 10% FBS. SK-BR-3 and NIH3T3 cells were transfected with pcDNA3.1-Myc, pcDNA3.1-Myc-CKIP-1 or pcDNA3.1-Myc-CKIP-D310+345A plasmids by Lipofectamine 2000 (Invitrogen) or FuGene 6 reagent (Roche) according to the manufacturer's instructions. Three days later, G418 (Invitrogen) was added into the medium (800  $\mu$ g/ml) for 2-3 weeks to select the stable transfectants.

### **Fluorescence analysis of CKIP-1**

For localization of CKIP-1 after TNF treatment (Supplementary figure S4), HepG2 cells were transfected with RFP-CKIP-1. Twenty-four hours later, the cells were deprived of serum overnight and treated with TNF plus CHX for the indicated time. The images were visualized using a confocal microscope (Bio-Rad, Radiance 2100<sup>TM</sup>).


**Fig. S1**



**Figure S1.** Analysis of cleavage of CKIP-1 by caspase-3 *in vitro*.

(A) Wild-type CKIP-1 and the D310A mutant were incubated with purified caspase-3 *in vitro*. Cleavage of wt-CKIP-1 generated a 35 kDa fragment, whereas D310A generated a 38 kDa fragment, suggesting that D310 is one cleavage site. The other one is located closely C-terminal of D310. (B) CKIP-1 truncates 1-337 and 148-409, in which the C-term1 and the N-terminal PH domain was deleted respectively, were subjected to cleavage *in vitro*. The former was cleaved into a slightly smaller fragment, confirming that a cleavage site exists close to residue 337. The band of the latter disappeared after incubation with caspase-3, possibly due to the fact that the cleaved products contain only 2 Met residues and therefore the signal is weak. (C) A series of point-mutants of CKIP-1 were cleaved by caspase-3 *in vitro*. The sizes of cleaved fragments were the same as that of wild-type CKIP-1, excluding the sites D74, D147, D194, D248 and D280 as cleavage sites, although the DLS74 motif conforms to the caspase-3 consensus sequence DXXD. (D) Alignment of human, mouse and rat CKIP-1 shows conserved caspase-3 cleavage sites (D310 and D345 in human) and conserved GSK3 and CK2 phosphorylation sites (S342 and S346 in human). Genbank accession numbers: human CKIP-1, AAK28027; mouse CKIP-1, NP\_075809; rat CKIP-1, XP\_227451.

## Fig. S2





**Figure S2. Efficiency of the cellular fractionation.**

P100, S100 and N fractions of SK-BR-3 cells were prepared as described (Safi *et al.*, 2004). To determine the efficiency of the cellular fractionation, the expression of Lamin A, nucleolin, Na<sup>+</sup>/K<sup>+</sup>-ATPase  $\alpha$ 1 and caspase-3 was detected by Western blotting analysis. Lamin A and nucleolin were used as nuclear marker proteins, while Na<sup>+</sup>/K<sup>+</sup>-ATPase  $\alpha$ 1 was used as the plasma membrane-localized protein. Caspase-3 was distributed in the cytoplasm and nucleus.

## Fig. S3


vector/NIH3T3



CKIP/NIH3T3


**Figure S3.** Stable expression of CKIP-1 in NIH3T3 cells clearly altered the cellular morphology.

**Fig. S4**



**Figure S4.** CKIP-1 causes membrane ruffling and vesicle formation in response to TNF. RFP-CKIP-1 was overexpressed in HepG2 cells and images were visualized after treatment of TNF (20 ng/ml) plus CHX (10  $\mu$ g/ml) for the indicated time. The images were visualized using a confocal microscope. The arrows indicate membrane ruffling and pinocytic vesicle formation both outside and inside the cells. *Scale bar*, 10  $\mu$ m.

**Fig. S5**



**Figure S5. Establishment of cells with diminished CKIP-1 expression by RNAi.**

(A) The sequence and relative position of the efficient CKIP-1 siRNAs. (B) HEK293 cells were transfected with pSuppressor-CKIP-1-siRNA or pSuppressor vector (1  $\mu$ g) for 48 hr, lysed and subjected to immunoblot analysis for CKIP-1, c-Jun and actin proteins.